Healthcare
Madrigal Pharmaceuticals, Inc.(MDGL)
Live Price
Offline$505.75
+1.18% today
1Y Change
+82.16%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $11.78B
- Revenue Growth
- +432.1%
- EPS Growth
- +41.3%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Madrigal Pharmaceuticals, Inc. (MDGL) is a Healthcare stock with a market cap of $11.78B and listed on NASDAQ. The stock last traded around $505.75 and up 82.2% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +432.1%, EPS growth of +41.3%, a dividend yield of 0.0%. What stands out right now is revenue +432.1%, EPS +41.3%, free cash flow +58.4% with operating margin -31.3% and ROIC -31.6%. Valuation already assumes a fairly strong business story at price/sales 12.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines MDGL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+432.1% vs +7.6% peer median
Operating Margin
Below sector median
-31.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +432.1% and EPS at +41.3%, with operating margin around -31.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +8.3% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | -4.6% | +0.9% | -9.0% |
2026 Feb 19, 2026 | -6525.0% | -0.4% | +2.1% | +4.0% |
2025 Nov 4, 2025 | -149.4% | +7.0% | +21.8% | +30.4% |
Benchmark Edge
MDGL vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MDGL
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MDGL Max Drawdown
-29.36%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MDGL and SPY.
Company Overview
Madrigal Pharmaceuticals, Inc.
NASDAQ Global Select
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ร agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
- Leadership
- William J. Sibold
- IPO Date
- Feb 6, 2007
- Employees
- 528
- Street Address
- Four Tower Bridge
- Mailing
- West Conshohocken, PA, 19428
- Region
- West Conshohocken, PA, US
- Reporting Currency
- USD
- Investor Line
- 267 824 2827
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 12.3
- Price/Book
- 19.1
Growth
- Revenue
- +432.1%
- EPS
- +41.3%
- Free Cash Flow
- +58.4%
Profitability
- Gross Margin
- 94.1%
- Operating Margin
- -31.3%
- Net Margin
- -30.1%
- ROE
- -43.8%
- ROIC
- -31.6%
Balance Sheet
- Debt/Equity
- 0.59
- Current Ratio
- 4.01
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.